CD19 and acute lymphoblastic leukemia: Indeed, primary pediatric BCP-ALL blasts are characterized by the expression of CD19, whereas CD20 is virtually negative, leading to lower interest in CD20-NKCEs, as well as possible therapies with anti-CD20 like rituximab.